Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?